VDA-1102 ointment is being developed under an IND from the FDA as a topical treatment for a variety of skin cancers.
It has completed a randomized, double-blinded, placebo-controlled, dose-escalation Phase 1 study in healthy older-adult volunteers which revealed no safety concerns in.
VDA 1102 AK
A Phase 2 B was was successfully completed in 2019 (NCT 03538951) demonstrating a 40% Complete Clearance and 80% lesions reduction in 50% of the population with a good skin permeability to the present formulation. A Phase 2C with a slightly enhanced skin permeability is programmed as soon as Corona Pandemics will allow.